Patent expiry intelligence isn’t just for lawyers—it’s for operators.
Most biosimilar strategies fail in the same place: timing. Not the timing of regulatory filings or the timing of market entry—timing of equipment decisions.
In biosimilars, the w…

Europe’s drug patent system is supposed to be predictable. But the clock doesn’t always run the way companies think.
If you’re building a pipeline—or underwriting the economics of a launch—your biggest risk isn’t just clinical failure. It’s the calenda…

Drug discovery timelines are getting squeezed from both sides—science and speed. The question isn’t whether AI can help. It’s whether it can help fast enough to matter.
A new post from DrugPatentWatch highlights a practical, increasingly urgent reality…

The “patent cliff” isn’t a cliff anymore—it’s a calendar.
For years, commercial market access teams have treated the loss of exclusivity as a single, dramatic moment: the day the patent expires, the day generics arrive, the day pricing resets. But th…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage in generics is supposed to be a clean story: win the patent case, launch early, capture meaningful market share, and monetize exclusivity before co…

The clock is ticking—and “generic” isn’t just a business decision. It’s a regulatory timing strategy.
In the race to launch a true generic, most teams obsess over the science: bioequivalence, formulation, manufacturing readiness. But the real finish li…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

Generic competition doesn’t just change prices—it redraws the map of who gets to sell, who gets to invest, and who gets paid.
That’s the real story behind Paragraph IV challenges and pay-for-delay settlements—the high-stakes patent “war” that often d…

Consumers Pay a “Trust Premium” for Branded Generics—Here’s Why That Matters for Pharma and Investors
Most people think the story of drug pricing is simple: branded drugs cost more than generics, and competition drives prices down. But the market reali…

AI is starting to “know” your drug the way investors do. The question is: do you know what it knows?
In pharma, we’ve spent years building competitive moats around data—clinical readouts, label language, patent estates, manufacturing constraints, payer…